The average P/S ratio for GMAB's competitors is 5.08, providing a benchmark for relative valuation. Genmab A/S Corp (GMAB) exhibits a P/S ratio of 3.34, which is -34.35% above the industry average. Given its robust revenue growth of 37.69%, this premium appearssustainable.